ARMD10
MCID: MCL030
MIFTS: 26

Macular Degeneration, Age-Related, 10 (ARMD10) malady

Categories: Genetic diseases, Eye diseases, Rare diseases, Neuronal diseases, Skin diseases

Aliases & Classifications for Macular Degeneration, Age-Related, 10

Aliases & Descriptions for Macular Degeneration, Age-Related, 10:

Name: Macular Degeneration, Age-Related, 10 54 66 13 69
Age Related Macular Degeneration 10 12 29
Armd10 12 66

Classifications:



External Ids:

OMIM 54 611488
Disease Ontology 12 DOID:0110022
MedGen 40 C1969108
MeSH 42 D008268

Summaries for Macular Degeneration, Age-Related, 10

UniProtKB/Swiss-Prot : 66 Macular degeneration, age-related, 10: A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.

MalaCards based summary : Macular Degeneration, Age-Related, 10, also known as age related macular degeneration 10, is related to macular degeneration, age-related, 1 and eye disease. An important gene associated with Macular Degeneration, Age-Related, 10 is TLR4 (Toll Like Receptor 4). The drugs Ranibizumab and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include eye.

Disease Ontology : 12 An age related macular degeneration associated with variation in the genomic region 9:112,100,000-127,500,000 (GRCh38). TLR4 has been put forth as a candidate gene.

Description from OMIM: 611488

Related Diseases for Macular Degeneration, Age-Related, 10

Symptoms & Phenotypes for Macular Degeneration, Age-Related, 10

Clinical features from OMIM:

611488

Drugs & Therapeutics for Macular Degeneration, Age-Related, 10

Drugs for Macular Degeneration, Age-Related, 10 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 347396-82-1 459903
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-02-2 5743
3
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
4
Verteporfin Approved, Investigational Phase 4,Phase 3,Phase 2 129497-78-5
5
Nepafenac Approved Phase 4,Phase 3,Phase 2 78281-72-8 151075
6
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 124-94-7 31307
7
Zinc Approved Phase 4 7440-66-6 32051 23994
8
Eplerenone Approved Phase 4 107724-20-9 150310 443872
9
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
10
Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
11
Lutein Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2 127-40-2 6433159 5368396
12
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
13
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-02-9 14985
14 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
15 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Antiemetics Phase 4,Phase 3,Phase 1,Phase 2
17 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1,Phase 2
19 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2
20 BB 1101 Phase 4,Phase 3,Phase 1,Phase 2
21 Dexamethasone 21-phosphate Phase 4,Phase 3,Phase 1,Phase 2
22 Dexamethasone acetate Phase 4,Phase 3,Phase 1,Phase 2 1177-87-3
23 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
24 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
25 HIV Protease Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
26 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
27 Hormones Phase 4,Phase 3,Phase 2,Phase 1
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
29 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
30
protease inhibitors Phase 4,Phase 3,Phase 1,Phase 2
31 Endothelial Growth Factors Phase 4,Phase 3,Phase 2,Phase 1
32 Mitogens Phase 4,Phase 3,Phase 2,Phase 1
33 Anti-Bacterial Agents Phase 4,Phase 1,Phase 2
34 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
35 Tocopherols Phase 4,Phase 3
36 Tocotrienols Phase 4,Phase 3
37 Vitamins Phase 4,Phase 3,Phase 1
38 Dermatologic Agents Phase 4,Phase 3,Phase 2
39 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
40 Photosensitizing Agents Phase 4,Phase 3,Phase 2
41 Analgesics Phase 4,Phase 3,Phase 2
42 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
43 Antibiotics, Antitubercular Phase 4
44 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2
45 Antirheumatic Agents Phase 4,Phase 3,Phase 2
46 Antibodies Phase 4,Phase 3,Phase 2
47 Antibodies, Monoclonal Phase 4,Phase 2
48 Immunoglobulins Phase 4,Phase 3,Phase 2
49 diuretics Phase 4,Phase 2
50 Diuretics, Potassium Sparing Phase 4

Interventional clinical trials:

(show top 50) (show all 242)
id Name Status NCT ID Phase
1 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4
2 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4
3 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4
4 Safety and Tolerability of Ranibizumab in Mono/Bilateral w-AMD Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye Completed NCT01986907 Phase 4
5 FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration Completed NCT01500915 Phase 4
6 Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial Completed NCT00751361 Phase 4
7 Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing Completed NCT01453920 Phase 4
8 Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4
9 Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) Completed NCT01775124 Phase 4
10 Visual Outcome in Patients With Symptomatic Macular PCV Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy. Completed NCT01846273 Phase 4
11 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema Completed NCT02036424 Phase 4
12 A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema Completed NCT01315275 Phase 4
13 CME With Different Fluidic Parameters Completed NCT01385852 Phase 4
14 Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery Completed NCT00494494 Phase 4
15 Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy Completed NCT00674323 Phase 4
16 Ranibizumab "Treat and Extend" in Diabetic Macular Edma Completed NCT01297569 Phase 4
17 A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion Completed NCT01277302 Phase 4
18 Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO Completed NCT01580020 Phase 4
19 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment Completed NCT01257815 Phase 4
20 Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration Recruiting NCT02944227 Phase 4
21 Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD Recruiting NCT02810808 Phase 4
22 Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye Recruiting NCT02581891 Phase 4
23 Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy Recruiting NCT01797861 Phase 4
24 Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy Recruiting NCT03079141 Phase 4
25 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Recruiting NCT01827722 Phase 4
26 Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study) Recruiting NCT02788877 Phase 4
27 Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema Recruiting NCT02471651 Phase 4
28 PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial Recruiting NCT02374060 Phase 4
29 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Recruiting NCT02684084 Phase 4
30 Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety Recruiting NCT02953938 Phase 4
31 Treatment of AMD With Rheohemapheresis /RHF/ Active, not recruiting NCT01943396 Phase 4
32 Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Primarily Intra-retinal Fluid) Treatment. Active, not recruiting NCT01972789 Phase 4
33 VITAL - Individualising Therapy for Neovascular AMD With Aflibercept Active, not recruiting NCT02441816 Phase 4
34 Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD Active, not recruiting NCT01958918 Phase 4
35 Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision Active, not recruiting NCT01795209 Phase 4
36 Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME. Active, not recruiting NCT02581995 Phase 4
37 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Active, not recruiting NCT02503540 Phase 4
38 Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy Not yet recruiting NCT02976194 Phase 4
39 TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection Terminated NCT01983579 Phase 4
40 Investigation of Macular Pigment Augmentation on Dark Adaptation Terminated NCT00478439 Phase 4
41 Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy Withdrawn NCT01666236 Phase 4
42 Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study Withdrawn NCT02902744 Phase 4
43 TTT Versus PDT for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration Unknown status NCT00260403 Phase 2, Phase 3
44 Subretinal Macugen® for Neovascular Age-Related Macular Degeneration Unknown status NCT00788177 Phase 3
45 A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib Completed NCT00242580 Phase 3
46 Improving Function in Age-Related Macular Degeneration Completed NCT00572039 Phase 3
47 Age-Related Eye Disease Study 2 (AREDS2) Completed NCT00345176 Phase 3
48 Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration Completed NCT00100009 Phase 3
49 French Evaluation Group Avastin Versus Lucentis Completed NCT01170767 Phase 3
50 Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride Completed NCT01802866 Phase 2, Phase 3

Search NIH Clinical Center for Macular Degeneration, Age-Related, 10

Genetic Tests for Macular Degeneration, Age-Related, 10

Genetic tests related to Macular Degeneration, Age-Related, 10:

id Genetic test Affiliating Genes
1 Age-Related Macular Degeneration 10 29

Anatomical Context for Macular Degeneration, Age-Related, 10

MalaCards organs/tissues related to Macular Degeneration, Age-Related, 10:

39
Eye

Publications for Macular Degeneration, Age-Related, 10

Variations for Macular Degeneration, Age-Related, 10

Expression for Macular Degeneration, Age-Related, 10

Search GEO for disease gene expression data for Macular Degeneration, Age-Related, 10.

Pathways for Macular Degeneration, Age-Related, 10

GO Terms for Macular Degeneration, Age-Related, 10

Sources for Macular Degeneration, Age-Related, 10

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....